BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/15/2023 12:44:08 AM | Browse: 286 | Download: 617
 |
Received |
|
2022-09-22 16:14 |
|
Peer-Review Started |
|
2022-09-22 16:16 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2022-11-30 22:45 |
|
Revised |
|
2022-12-18 14:40 |
|
Second Decision |
|
2023-01-05 03:42 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2023-01-05 19:49 |
|
Articles in Press |
|
2023-01-05 19:49 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2023-01-13 07:25 |
|
Typeset the Manuscript |
|
2023-02-07 06:41 |
|
Publish the Manuscript Online |
|
2023-02-15 00:44 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Immunology |
| Manuscript Type |
Review |
| Article Title |
“Cold” colorectal cancer faces a Bottleneck in immunotherapy
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Jia-Liang Liu, Ming Yang, Jun-Ge Bai, Zheng Liu and Xi-Shan Wang |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Zheng Liu, FASCRS, MD, PhD, Professor, Department of Colorectal Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021, China. zheng.liu@cicams.ac.cn |
| Key Words |
Immunotherapy; “Cold” colorectal cancer; Immune checkpoint inhibitors |
| Core Tip |
Immune checkpoint inhibitors (ICIs) are usually produced by antibodies, and their effectiveness relies on the antitumor effects of immune cells (especially T cells). Colorectal cancer (CRC) is one of the most common forms of cancer worldwide. only a limited number of patients are currently benefiting from ICIs owing to limitations such as individual differences and low response rates. In this review, we discuss the classification and differences between hot and cold CRC and the current status of research on cold CRC, and summarize the treatment strategies and challenges of immunotherapy for cold CRC. |
| Publish Date |
2023-02-15 00:44 |
| Citation |
Liu JL, Yang M, Bai JG, Liu Z, Wang XS. “Cold” colorectal cancer faces a Bottleneck in immunotherapy. World J Gastrointest Oncol 2023; 15(2): 240-250 |
| URL |
https://www.wjgnet.com/1948-5204/full/v15/i2/240.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v15.i2.240 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
